Liposomes containing Candida albicans ribosomes as a prophylactic vaccine against disseminated candidiasis in mice

Vaccine

Volumn 15, Issue 2, 1997, Pages 220-224

  Eckstein, M ^a   Barenholz, Y ^b   Bar, L K ^b   Segal, E ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Candida albicans; Liposomes; Ribosomes; Vaccine

Indexed keywords

CANDIDA ALBICANS VACCINE; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; LIPOSOME;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RIBOSOME; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION;

ANIMALS; ANTIBODIES, FUNGAL; CANDIDIASIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FUNGAL VACCINES; HYPERSENSITIVITY, DELAYED; IMMUNITY, CELLULAR; LIPOSOMES; MICE; MICE, INBRED ICR; RIBOSOMES;

EID: 0031081707     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(96)00137-5     Document Type: Article

References (28)

1. 1 Edwards, E.J. Candida species. In: Principles and Practice of Infectious Diseases, Vol. 2. Churchill Livingstone, London, 1995, pp. 2289-2306
2. 2 Stein, D.K. and Sugar, A.M. Fungal infections in the immunocompromised host. Diagn. Microbial. Infect. Dis. 1989, 12, 221S-228S
3. 3 Wingard, J.R. The use of fluconazole prophylaxis in patients with chemotherapy-induced neutropenia. Leuk-Lymphoma 1992, 8, 353-359
4. 4 Anaissie, E. Opportunistic mycosis in the immunocompromised host: experience at a cancer center and review. Clin. Infect. Dis. 1992, 14Suppl. 1, 543-553
5. 5 Youmans, A.S. and Youmans, G.P. Immunogenic activity of a ribosomal fraction obtained from Mycobacterium tuberculosis. J. Bact. 1965, 89, 1291-1298
6. 6 Gregory, L.R. Microbial ribosomal vaccines. Rev. Infect. Dis. 1986, 8, 208-217
7. 7 Elad, D. and Segal, E. Fungal ribosomal vaccines. II. Dermatophyte vaccine - initial studies on the antigenicity of a crude ribosomal fraction from Microsporum canis. Mycophathologia 1989, 105, 45-51
8. 8 Levenson, V.I. and Erogova, T.P. Protective ribosomal preparation from Shigella sonnei as a parenteral candidate vaccine. Infect. Immun. 1991, 59, 3610-3618
9. 9 Levy, R., Segal, E. and Eylan, E. Protective immunity against murine candidiasis elicited by Candida albicans ribosomal fraction. Infect. Immun. 1981, 31, 874-878
10. 10 Levy, R., Segal, E. and Eylan, E. Detection of antibodies against Candida albicans ribosomes by the enzyme linked immunosorbent assay. Mycopathologia 1984, 87, 167-170
11. 11 Levy, R., Segal, E., Eylan, E. and Bar-Nea, L. Cell mediated immunity following experimental vaccinations with Candida albicans ribosomes. Mycopathologia 1983, 83, 161-168
12. 12 Segal, E. and Sandovsky-Losica, H. Experimental vaccination with Candida albicans ribosomes in cyclophosphamide-treated animals. Sabouraudia 1981, 19, 267-273
13. 13 Segal, E., Sandovsky-Losica, H. and Nussbaum, S. Immune responses elicited by vaccinations with Candida albicans ribosomes in cyclophosphamide treated animals. Mycopathologia 1985, 89, 113-118
14. 14 Segal, E., Spongin, E. and Bar-Nea, L. Induction of protection against candidiasis in tumor bearing mice by vaccination with Candida albicans ribosomes. J. Med. Vet. Mycol. (Sabouradia) 1987, 25, 355-363
15. 15 Segal, E., Nussbaum, S. and Bar-Nea, L. Protection against systemic infections with various Candida species elicited by vaccination with Candida albicans ribosomes. J. Med. Vet. Mycol. (Sabouradia) 1985, 23, 275-285
16. 16 Alving, R.C. Liposomes as carriers of antigens and adjuvants. J. Immun. Meth. 1991, 140, 1-13
17. 17 Machy, P. and Leserman, L. Composition, properties and preparation of liposomes. In: Liposomes in Cell Biology and Pharmacology. Les editions 1987, pp. 8-31
18. 18 Gregoriadis, G. Immunological adjuvants: a role for liposomes. Immun. Today 1990, 11, 89-97
19. 19 Alving, B.C. and Richards, R.L. Liposomes containing lipid A: a potent nontoxic adjuvant for a human malaria sporozoite vaccine. Immunol. Lett. 1990, 25, 275-279
20. 20 Storm, G., Oussoren, C., Peeters, P.A.M. and Barenholz, Y. Tolerability of liposomes in vivo. In: Liposome Technology. CRC Press, Boca Raton, FL, 1993, Vol. 3, pp. 345-383
21. 21 Bradford, M.M. A rapid and sensitive method for quantitation of microgram quantities of protein, utilizing the principle of protein dye binding. Analyt. Biochem. 1976, 72, 248-254
22. 22 Herbert, D., Phillips, P.J. and Strange, R.E. Chemical analysis of microbial cells. In: Methods in Microbiology. Academic Press, New York, 1971, Vol. 5B, pp. 210-336
23. 23 Diminsky, D., Reimann, Z.J., Schirmbeck, R. and Barenholz, Y. Structural and functional characterization of liposomal recombinant hepatitis B vaccine. J. Liposome Res. 1996, 6, 289-304
24. 24 Kirby, C. and Gregoriadis, G. Dehydration-rehydration vesicles: a simple method for high yield drug entrapment in liposomes. Biotechnology 1984, 11, 979-984
25. 25 Crowle, A.J. Delayed hypersensitivity in the mouse. Adv. Immun. 1975, 20, 197-264
26. 26 Barenholz, Y. and Amselem, S. Quality control assays in the development and clinical use of liposome based formulations. In: Liposome Technology. CRC Press, Boca Raton, FL, 1993, Vol. 1, pp. 527-616
27. 27 Verma, I., Panchol, P. and Knuller, G.K. Comparative study of the adjuvancity of FIA and phosphatidylcholine liposomes for purified mycobacterial RNA. J. Liposome Res. 1995, 5, 227-240
28. 28 Pancholi, P. and Vinayak, V.K. Immunogenicity of ribonucleic acid protein fraction of Mycobacterium tuberculosis encapsulated in lipsomes. J. Med. Microbiol. 1989, 29, 131-138